Recent drug development efforts targeting Alzheimer's disease (AD) have failed to produce
effective disease-modifying agents for many reasons, including the substantial …

The history of brain drug delivery is reviewed beginning with the first demonstration, in 1914,
that a drug for syphilis, salvarsan, did not enter the brain, due to the presence of a blood …

Antiamyloid antibodies have been used to reduce cerebral amyloid-beta (Aβ) load in
patients with Alzheimer's disease. We applied focused ultrasound with each of six monthly …

The intricate and delicate anatomy of the brain poses significant challenges for the treatment
of cerebrovascular and neurodegenerative diseases. Thus, precise local drug delivery in …

The main limitation to the success of central nervous system (CNS) therapies lies in the
difficulty for drugs to cross the blood–brain barrier (BBB) and reach the brain. Regarding its …

Alzheimer's disease (AD) is the most common form of dementia and may contribute to 60–
70% of cases. Worldwide, around 50 million people suffer from dementia and the prediction …

Cerebral endothelial cells and their linking tight junctions form a unique, dynamic and multi-
functional interface, the blood-brain barrier (BBB). The endothelium is regulated by …

Background Focused ultrasound (FUS)-mediated blood–brain barrier (BBB) opening has
shown efficacy in removal of amyloid plaque and improvement of cognitive functions in …

Neurodegenerative disorders involve the slow and gradual degeneration of axons and
neurons in the central nervous system (CNS), resulting in abnormalities in cellular function …

OBJECTIVE MRI-guided low-intensity focused ultrasound (FUS) has been shown to
reversibly open the blood-brain barrier (BBB), with the potential to deliver therapeutic agents …